Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies. - Wikidata - wikimedia - TriplyDB

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

http://www.wikidata.org/entity/Q37038482

about

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.Identification of genomic alterations in oesophageal squamous cell cancer.Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma.Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.

P2860

Q33424270-CC620273-F162-4C12-AD5A-146AA5B4DFB6 Q33688421-32E87F61-D567-4584-ACEA-666BBD2E9140 Q34412178-D40C951A-BD73-4F2A-BEB0-E2BC156AA7E9 Q35763725-C8EAC7F1-6C72-40CB-A64F-6630147546D3 Q37475210-62D8BD4B-3973-46CC-AB35-8F55F9C36F03 Q47098880-317300D5-E23E-4984-8659-B65F3EC4167D Q55027485-0F56E6C5-AFA4-45C3-8470-6476CE09DFCB

P2860

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

http://www.wikidata.org/entity/Q37038482

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

@en

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

@nl

type

label

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

@en

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

@nl

prefLabel

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

@en

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

@nl

P1433

Q37038482-BAB1371E-57DB-46A2-80FF-01263D8B23FB

P1476

Q37038482-54B8229D-C5AE-4B29-9ACF-9604D902522D

P2093

Q37038482-B804BDB5-7D6F-4FD2-BCA9-DF15782C26FF

Q37038482-C8FD3A8E-2F37-4562-9FC5-14F1DAAB10F6

P2860

Q37038482-036AD227-5D2F-4CDE-B07C-B9700659DAF1

Q37038482-09B308B0-FAE8-4AFE-9C02-C98C73698893

Q37038482-140B7FC3-2040-4497-9D5C-0088D6C430B0

Q37038482-16D81717-DE89-4276-B756-8208BF7549BF

Q37038482-1AFEA942-7705-4EC3-A3D2-14BD731CA533

Q37038482-2840A8E3-B53C-4C68-AAA4-D1E5F7021F8E

Q37038482-2D88B35C-E74E-4BEF-84D6-8497E4BC10B5

Q37038482-2E8C4D78-C19D-4555-8D65-4D435A112F5F

Q37038482-2F6C393F-FE14-49CF-9CE5-A793DD2F83FC

Q37038482-30FFD753-72F8-4342-A663-F83DF110EBA5

P304

Q37038482-A96B0180-5E0E-4E8B-812A-C5D040DC5D75

P31

Q37038482-CCF28B0D-C02B-4B6B-90FC-24C18634AB71

P356

Q37038482-5EB06E9D-73EC-4FB3-8EB7-E34BB531948A

P433

Q37038482-FADDB145-E306-430E-9011-06C1DF85CF79

P478

Q37038482-8EF7C8A5-9D64-48C1-8371-64311DF81F87

P577

Q37038482-5FEF8D6E-F572-4B26-B48F-0149AA4457AA

P5875

Q37038482-4E0820D0-6F2C-4A8C-AB61-39D8C2D0E428

P698

Q37038482-C8285AFB-404B-4F9C-AB16-9870533356F7

P932

Q37038482-9BDD21F5-02FF-4033-9F96-C728BB297B12

P356

THEONCOLOGIST.2013-0130

P1433

P1476

Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.

@en

P2093

Patrick M Forde

http://www.w3.org/2001/XMLSchema#string

Ronan J Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.

Frequent mutation of the p53 gene in human esophageal cancer

Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)

Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

P304

823-832

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0130

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

249321939

http://www.w3.org/2001/XMLSchema#string

P698

23853247

http://www.w3.org/2001/XMLSchema#string

P932

3720637

http://www.w3.org/2001/XMLSchema#string